Title
Nitric oxide mediates the survival action of IGF-1 and insulin in pancreatic β cells
Date Issued
01 February 2008
Access level
metadata only access
Resource Type
journal article
Author(s)
Cahuana G.M.
Hmadcha A.
Ramírez R.
Cuesta A.L.
Soria B.
Martin F.
Bedoya F.J.
Regenerative Medicine (CABIMER)-University Pablo de Olavide
Abstract
Generation of low levels of nitric oxide (NO) contributes to beta cell survival in vitro. The purpose of this study was to explore the link between NO and the survival pathway triggered by insulin-like growth factor-1 (IGF-1) and insulin in insulin producing RINm5F cells and in pancreatic islets. Results show that exposure of cells to IGF-1/insulin protects against serum deprivation-induced apoptosis. This action is prevented with inhibitors of NO generation, PI3K and Akt. Moreover, transfection with the negative dominant form of the tyrosine kinase c-Src abrogates the effect of IGF-1 and insulin on DNA fragmentation. An increase in the expression level of NOS3 protein and in the enzyme activity is observed following exposure of serum-deprived RINm5F cells to IGF-1 and insulin. Phosphorylation of IRS-1, IRS-2 and to less extent IRS-3 takes place when serum-deprived RINm5F cells and rat pancreatic islets are exposed to either IGF-1, insulin, or diethylenetriamine nitric oxide adduct (DETA/NO). In human islets, IRS-1 and IRS-2 proteins are present and tyrosine phosphorylated upon exposure to IGF-1, insulin and DETA/NO. Both rat and human pancreatic islets undergo DNA fragmentation when cultured in serum-free medium and IGF-1, insulin and DETA/NO protect efficiently from this damage. We then conclude that generation of NO participates in the activation of survival pathways by IGF-1 and insulin in beta cells. © 2007 Elsevier Inc. All rights reserved.
Start page
301
End page
310
Volume
20
Issue
2
Language
English
OCDE Knowledge area
Biología celular, Microbiología
Subjects
Scopus EID
2-s2.0-37549060347
PubMed ID
Source
Cellular Signalling
ISSN of the container
08986568
Sponsor(s)
This work was supported by grants from Dirección General de Investigación Científica y Técnica (SAF2006/13686), Junta de Andalucía (CTS576) to FJ. Bedoya; Instituto de Salud Carlos III (GO3/171, GO3/210 and GO3/212) to B. Soria. Dirección General de Investigación Científica y Técnica (CYT-836, SAF2005-08014), Spanish Novo Nordisk Pharma grant and Instituto de Salud Carlos III (C03/08 and 02/PIos1473)) to AL. Cuesta.; Dirección General de Investigación Científica y Técnica (SAF2003-03307; SAF2006-06673), Junta de Andalucía (exp. 0009/06), Instituto de Salud Carlos III (RCMN C03/08) to F. Martín and Instituto de Salud Carlos III (ISCIII-RETIC RD06/0015) to F. Martín, B. Soria and FJ Bedoya.
Sources of information:
Directorio de Producción Científica
Scopus